New Job Opportunity

Colorcon Unveils Cutting-Edge Pharmaceutical Packaging Site in Malaysia

Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the pharmaceutical and nutraceutical industries, announced the grand opening of a new, state-of-the-art film coating manufacturing facility in Johor Malaysia. The 200,000 square-foot facility will immediately employ 30 people and will serve as the production hub for film coatings in the Asia Pacific region. Designed with cutting-edge technology and energy-efficient systems, the new plant reinforces Colorcon's dedication to industry innovation, superior quality, regulatory leadership and environmental stewardship. Simon Tasker, CEO of Colorcon, said of the project: "We are thrilled to open this world-class facility to support our pharmaceutical customers throughout Asia. This investment is aligned with our long-term vision to strengthen and de-risk our supply model for film coatings worldwide. Our goal is to anticipate market growth, adding capacity to ensure we are always a step ahead of demand. This is just one of many development projects currently in our pipeline to support our credo of 'we're everywhere our customers need us to be." Willem Hoogwater, Managing Director at Colorcon, added: "This is a monumental achievement for the local team, and I commend everyone who has played a part in bringing this facility to completion. We're proud to offer superior film coating technology and a world-class facility to this rapidly growing region. Malaysia has quickly become an important hub for high-value pharmaceutical manufacturing, and we're proud to support the local economy with an investment like this. We look forward to serving our regional customers even more efficiently for many years to come as a result."

AstraZeneca’s $50B U.S. Investment to Create Tens Thousands of Jobs

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. Howard Lutnick, US Secretary of Commerce, said: “For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.” Governor Glenn Youngkin, Commonwealth of Virginia, said: “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.” Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”

Bakar Labs Unveils Expansion Space for Growing Life Science Startups

Bakar Labs, the University of California, Berkeley's flagship incubator for life science, energy, and materials startups, announced the launch of a new building on campus that will provide critical infrastructure for life science startups scaling beyond the earliest stages. Launched in partnership with the Innovative Genomics Institute (IGI), the IGI-Bakar Labs building will house expansion space for biotech companies transitioning out of early incubators as they exceed 20-30 employees. This space will help retain high-potential startups in the Berkeley ecosystem by offering state-of-the-art labs and offices, flexibility, community support, and proximity to campus resources so companies can continue to grow. Construction is projected to be complete in late 2028. "It's important to keep startups in Berkeley because they're not just creating jobs for skilled graduates, they're feeding a cycle of innovation," said David Schaffer, a UC Berkeley professor of chemical and biomolecular engineering and director of QB3 and Bakar Labs. "When leaders stay connected to the ecosystem, they return to Bakar Labs as mentors, advisors and role models. That continuity strengthens the entire community." "Bakar Labs gave us the foundation to move fast and stay focused during our earliest days," said Sophia Lugo, CEO & co-founder of Radar Therapeutics. "The community, resources, and collaborative energy were unlike anything else in the Bay Area. As we've grown, it's meant everything to have a path forward that lets us scale without losing that connection. This new expansion space is exactly what companies like ours need to keep building, without leaving behind the ecosystem that helped us get here." "Bakar Labs provides what every biotech startup needs—an environment that accelerates both scientific rigor and company formation. At Ray Therapeutics, this ecosystem helped us refine our strategy, build a strong team, and move quickly toward the clinic. It's more than a lab space, it's an ecosystem for life science companies," said Peter Francis, MD, PhD, CSO and CMO at Ray Therapeutics. The new facility builds on Bakar Labs' success since launching its first location on the south side of campus, in a landmark building originally home to the Berkeley Art Museum and renovated into a biotech incubator that has helped nurture more than 45 seed-stage startups. Collectively, since 2021 Bakar-incubated companies have raised more than $700 million in capital and created hundreds of jobs across the region.

GenesisM Breaks Ground on New Biomanufacturing Facility in Massachusetts

GenesisM, a joint venture between Bain Capital Real Estate (“Bain Capital”) and Botanic Properties (“Botanic”), announced the official groundbreaking of its 154,000-square-foot Class A biomanufacturing facility at 45 Crosby Drive in Bedford, Massachusetts. The project marks a significant step forward in addressing the critical need for purpose-built life sciences manufacturing infrastructure in the Greater Boston region. Bain Capital and Botanic formed GenesisM to create best-in-class real estate solutions tailored to the clinical and commercial production needs of life science tenants. GenesisM’s proprietary Enhanced Core design provides a robust initial build-out that reduces tenant fit-out time and capital costs, helping companies better align their manufacturing spend and scale with product maturity. Strategically located along the Route 3 corridor and with proximity to Kendall Square’s renowned life sciences ecosystem, the Bedford facility is designed to support multiple tenants operating independently within highly regulated manufacturing suites. Each tenant will have access to dedicated infrastructure and building systems designed to meet stringent operational requirements. “This groundbreaking marks a major milestone in the evolution of GenesisM,” said Joshua Zinns, Managing Principal of Botanic Properties. “We are proud to advance our mission of delivering flexible, capital-efficient biomanufacturing facilities that help companies bring innovative therapies to market faster and more efficiently. We are particularly pleased to be able to deliver this project in Bedford, MA, which is one of the most forward-thinking communities for life science and technology companies.”

Varda Space Secures $329M in Series C to Advance Microgravity Biotech

Varda Space Industries announced a Series C fundraising round today, bringing the total amount of capital raised by the microgravity-enabled life sciences company to $329 million. The $187 million fundraise was led by Natural Capital and Shrug Capital, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital, and Also Capital. Varda's orbital laboratories are the first to process materials outside the International Space Station and mark the beginnings of commercial expansion into low Earth orbit. Due to the lack of gravity, materials such as the active pharmaceutical ingredients in medicines crystallize differently than they would on Earth, creating novel drug formulations that would otherwise be impossible. In addition to its core competencies in the life sciences, Varda operates a hypersonic testbed for government partners, working to utilize the W-series reentry vehicle to advance new technologies. The reentry capsules reach Mach 25 on their journey from space to Earth, offering a valuable, real-world flight environment for testing subsystems such as thermal protective materials, navigation, communication, and sensors. "With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world's first microgravity-enabled drug formulation," said Varda CEO Will Bruey. Varda has expanded its footprint terrestrially as well, opening an office in Huntsville, Ala. and a new 10,000 square foot laboratory space in El Segundo, which will allow its pharmaceutical scientists to begin working on developing processes to crystallize biologics, such as monoclonal antibodies. As of 2022, the market size for monoclonal antibodies is estimated to be $210.06 billion. "Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy," said Chief Science Officer Adrian Radocea. "By expanding, we can support work on more complex molecules and ultimately increase cadence to achieve the turnaround times the pharmaceutical industry expects." Varda has hired a world-class pharmaceuticals team that will work at the new lab in El Segundo, including structural biologists and crystallization scientists with decades of prior experience in structural biology and crystallization across top 20 pharmaceutical companies. "Through multiple flights, the Varda team has proven a repeatable orbital-reentry capability, attracted serious DoD demand, and is now turning that momentum toward a world-class crystallization lab that will unlock microgravity manufacturing for life-changing medicines and other high-value materials," said Ravi Tanuku, General Partner at Natural Capital and a member of the Varda Board of Directors. "We're excited to support Varda as it turns this bold vision into reality."

New BioSpring Site Brings 200 Biotech Jobs to Offenbach

BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs Dr. Sylvia Wojczewski, CEO of BioSpring: “With our investment in Offenbach, we are setting new standards in nucleic acid drug substance manufacturing,” explained Wojczewski. “In the future, we’ll be able to produce nucleic acids for therapeutic applications on a ton scale. This allows us to support our clients’ growth by offering new high-volume capacity. The investment underscores our position as a global leading industrial manufacturer of synthetic nucleic acids.” The new building complex will include three interconnected structures: a manufacturing and warehouse facility, an office area for quality control and production teams, and a glass atrium designed for events. An external solvent tank farm will also be built. Production will be conducted under GMP (Good Manufacturing Practice) conditions, a quality standard that ensures the highest levels of product quality, purity, and safety. In total, the complex will offer over 15,200 m² (approx. 164,000 ft²) of gross floor area and will employ around 200 people. In the long term, BioSpring aims to create additional jobs at the Innovation Campus in Offenbach. The investment amounts to several hundred million euros, with completion planned for the end of 2027. “The city of Offenbach has supported our project from day one, from every level of staff up to the mayor himself. Even in challenging moments, everyone has been focused on finding solutions. We feel reassured in our decision to choose Offenbach,” said Wojczewski, also commending the regional government office in Darmstadt for their professional collaboration. With nearly three decades of experience, BioSpring is a leading company and commercial provider specializing in the manufacturing and analysis of therapeutic nucleic acids, particularly oligonucleotides, from small preclinical quantities to full-scale commercial production. These short, synthetically produced RNA sequences hold the potential for groundbreaking new therapies, including treatments for cancer and Alzheimer’s disease. They also offer entirely new therapeutic possibilities for the treatment of rare genetic disorders—potentially enabling the complete cure of diseases that were previously considered incurable. With the investments now underway in Offenbach, BioSpring will further strengthen its global leadership in the production and analysis of synthetic nucleic acids.

Altus Community Healthcare Seeks Skilled ER Physicians Amid Expansion

As the largest provider of emergency care in Texas, Altus Community Healthcare is recognized for its broad network of freestanding emergency rooms and micro-hospitals that deliver fast, patient-centered care across the state. Known for clinical excellence and community responsiveness, Altus continues to grow—driven by the need to recruit top-tier physician talent aligned with its mission to provide accessible, high-quality care. To support this goal, Altus partnered with Rave Health to strengthen its recruitment strategy and meet increasing staffing demands. Rather than pursuing a one-size-fits-all approach, Altus prioritized a tailored solution that reflects the organization's values, operational model, and long-term vision. The resulting strategy, customized to Altus' unique footprint in emergency medicine, included a coordinated, multi-channel outreach plan. Dynamic landing pages highlighted Altus's innovative care model and leadership in emergency services. Personalized email campaigns and direct mail emphasized its commitment to patient outcomes, state-of-the-art facilities, and supportive work environments. Targeted LinkedIn ads further expanded Altus' reach to experienced physicians seeking meaningful roles in high-demand care settings. This focused approach elevated Altus' visibility within the physician community and reinforced its identity as an employer of choice in emergency medicine. By leveraging marketing channels that align with its clinical values and organizational strengths, Altus established a cohesive, compelling recruitment presence—while continuing to deliver on its promise of excellence in care.

Axplora’s €35M Farmabios Expansion to Drive Growth and Job Creation in Italy

Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company’s longstanding commitment to serving the evolving needs of its customers through strategic investment and innovation. This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s total recent investment in Farmabios to over €80 million. The addition of 62,000 square meters of new development in 2026 will more than double the total footprint of the site to 108,000 square meters. This will be more than ten times its original size Farmabios began commercial operations in 1968. “This expansion is not just a matter of scale, it’s about shaping the future of pharmaceutical manufacturing,” said Mario Di Giacomo, Managing Director of Farmabios. “We are investing with purpose: to enhance our capabilities, support our partners, and continue leading with innovation and integrity.” This expansion follows a period of accelerated growth at Farmabios over the last five years, during which €45m has already been invested. Key initiatives include the construction of a new micronisation department, expanded warehouse capacity, and the RS40 building – a state-of-the-art unit purpose- built for the safe and efficient handling of High Potent APIs (HPAPIs). Designed in accordance with the most stringent safety and containment standards, RS40 employs acomprehensive exposure control strategy, including a layout based on exposure zoning that ensuresstrict segregation of high-potency operations within dedicated suites. The facility supports anOccupational Exposure Limit (OEL) as low as 10 nanograms per cubic meter and complies fully withOEB5 containment criteria. Its design incorporates stand-alone workshops and fully isolated processrooms to mitigate cross-contamination risks, offering maximum protection for both operators andproducts. In addition, the micronisation rooms are equipped with isolators specifically designed forHPAPI processing, ensuring safe handling of potent compounds at every stage. This period of investment has been matched by significant talent growth: between 2020 and 2024,Farmabios’ workforce nearly doubled, from approximately 150 to nearly 300 employees, reflecting thesite’s strategic importance within Axplora’s global network. This trend is likely to continue with theexpansion of the site. “The Farmabios site reflects Axplora’s commitment to being a proactive, science-led, and sustainablepartner,” said Martin Meeson, CEO of Axplora. “Every investment we make is guided by the ambitionto deliver greater value to our customers, while raising the bar in reliability, speed and efficiency.”

Vetter Breaks Ground on New Clinical Manufacturing Site in Chicago Area

Vetter celebrated the start of construction on its new clinical manufacturing site in the Chicago area with an official groundbreaking ceremony. The state-of-the-art facility, which is being built in Des Plaines, Illinois, is expected to be ready for media fill by the end of 2029. This $285 million investment will strengthen Vetter’s position as a leading global partner for aseptic manufacturing in early clinical development. The new site provides additional capacity for small-batch production of novel active ingredients and includes space for warehouses, laboratories, and administrative offices. The approximately 860,000 square feet site has the capacity to accommodate future expansion, contingent on global demand and additional strategic investments. "This project marks another milestone in our international growth strategy. It underscores our commitment to quality and innovation, as well as our responsibility to our customers, partners, and patients around the world" Said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board. With its new location, Vetter is strengthening its presence in the North American market and supplementing its existing clinical network in Skokie, Illinois and Rankweil, Austria.

WuXi XDC Nears Completion of Singapore Site, Begins Hiring Surge

WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its manufacturing site at Tuas Biomedical Park in Singapore has been successfully achieved. This milestone signifies that this manufacturing site, spanning approximately 25,000 square meters, will now officially transition into the facility C&Q (Commissioning and Qualification) stage. The Singapore site is expected to commence operations by the end of 2025 and Good Manufacturing Practice (GMP) manufacturing in 2026. Upon that, the site will offer comprehensive production capabilities from the preclinical stage to commercialization. As a critical component of WuXi XDC's global strategy, the Singapore site has demonstrated exceptional progress, adhering to the perfect execution and the "WuXi Speed" to provide customers with agile and flexible end-to-end CRDMO services. According to current capacity plan, the site is anticipated to create more than 500 job opportunities and over 100 people have joined our company so far. Dr. Jimmy Li, CEO of WuXi XDC, stated, " The rapid mechanical completion of our Singapore site marks a critical pillar in our 'Global Dual-Sourcing' strategy. This global site will form a worldwide network alongside our Wuxi, Changzhou, and Shanghai sites, delivering end-to-end CRDMO services to global customers. This accomplishment showcases the full support of the partners for the construction of Singapore site, our deep understanding of global market demands, our ability to respond swiftly and the robust execution capabilities of our team. Looking ahead, we remain committed to advancing our one-stop model and global supply network, collaborating with global partners to promote the diversified and sustainable development of bioconjugates." The Singapore site serves as a world-class, one-stop bioconjugates manufacturing center, integrating antibody intermediates, drug substance (DS), and drug products (DP). It strictly adheres to international certification standards and utilizes an advanced modular factory design. Key features include state-of-the-art antibody intermediates production lines, bioconjugate DS and DP production lines, MSAT lab, quality control, intelligent warehousing, and other utility support areas. Equipped with cutting-edge isolator filling lines, fully automated material transfer systems, and digital production management systems, the Singapore site supports multi-level demands ranging from small-scale clinical supplies to large-scale commercial manufacturing, including up to 2,000 liters per batch of mAb/DS, and 8 million vials of DP per year. These capabilities ensure the efficient advancement of projects across various stages while maintaining adherence to the highest quality standards. The Singapore site will be operated under the highest international quality assurance standards, fully complying with Good Manufacturing Practice (GMP) regulations established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). This ensures comprehensive compliance throughout the production process, from antibody intermediates and DS to DP, enabling seamless product release globally. Additionally, the site incorporates environmentally friendly practices, utilizing certified eco-friendly products and implementing strict recycling and waste disposal systems to promote sustainability and enhance the company's ESG management level.